About
Tissue Regenix Group is an international medical technology company based in Leeds, England, specializing in regenerative medicine. The company focuses on developing innovative products using its proprietary technologies: dCELL®, which addresses soft tissue needs, and BioRinse™, which provides sterile bone allografts. Their flagship product, DermaPure®, is a decellularized dermal allograft designed to support better clinical outcomes in soft tissue repair. The company’s technology features a patented decellularization process that effectively removes DNA and cellular material from donor tissues, minimizing the risk of rejection while preserving the tissue's natural structure. Tissue Regenix aims to improve patient care across various surgical fields, including BioSurgery, Orthopaedics, Dental, General Surgery, Plastic Surgery, Urology/Gynaecology, Ophthalmology, and Cardiac surgery. They distribute their products through strategic partnerships and direct sales globally, positioning themselves as leaders in regenerative medicine innovation.
Technologies
Keywords
Company Information
- Employees82
- Founded2006
- Annual Revenue$28646000
- Total Funding$73370159
Location
Unit 6 Astley Way, Swillington, England, United Kingdom, LS26 8XT
